Screener
Kymera Therapeutics KYMR Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | $136,188 | $163,148 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, 82,788,253 and 81,323,532 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 8 | 8 |
| Additional paid-in capital | 2,712,811 | 2,643,817 |
| Accumulated deficit | (1,196,406) | (1,065,961) |
| Accumulated other comprehensive (loss) income | (7,157) | 1,800 |
| Total stockholders’ equity | 1,509,256 | 1,579,664 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's common stock?
- Kymera Therapeutics (KYMR) reported common stock of $8K in Q2 2026.
- How has Kymera Therapeutics's common stock changed year-over-year?
- Kymera Therapeutics's common stock increased by 14.3% year-over-year, from $7K to $8K.
- What is the long-term trend for Kymera Therapeutics's common stock?
- Over 5 years (2020 to 2025), Kymera Therapeutics's common stock has grown at a 14.9% compound annual growth rate (CAGR), from $4K to $8K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Kymera Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude